Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677741 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
A Phase 1 study of Neoplasms, Brain, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 20
- Study locations
NCT01677741 is a Phase 1 study of Neoplasms, Brain that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 85 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT01677741, a Phase 1 study of Neoplasms, Brain, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a 2-part, Phase I/IIa, multi-center, open label, study in pediatric and adolescent patients with advanced BRAF V600 mutation-positive solid tumors. Part 1 was a dose escalation study in patients with any BRAF V600 mutation-positive solid tumor using a modified Rolling 6 Design (RSD). Part 2 was an expansion study to further evaluate the safety, tolerability, and clinical activity of dabrafenib in 4 tumor-specific pediatric populations. Patients participated in only either part 1 or part 2 of the study.
Conditions Studied
Interventions
- DRUG Dabrafenib
Study Locations (20)
Other
- Novartis Investigative Site - Copenhagen
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Toulouse
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Jerusalem
Arizona
- Novartis Investigative Site - Phoenix
California
- Novartis Investigative Site - Orange
Maryland
- Novartis Investigative Site - Baltimore
Massachusetts
- Novartis Investigative Site - Boston
New York
- Novartis Investigative Site - New York
Ohio
- Novartis Investigative Site - Cincinnati
Tennessee
- Novartis Investigative Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2013-05-23 |
| Est. Completion | 2020-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677741
The ClinicalTrials.gov registry entry for NCT01677741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Brain appearing as the primary indexed condition, and to 1 intervention - of which Dabrafenib is the first listed.
NCT01677741 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT01677741 about?
NCT01677741 is a clinical study titled "A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects". This was a 2-part, Phase I/IIa, multi-center, open label, study in pediatric and adolescent patients with advanced BRAF V600 mutation-positive solid tumors. Part 1 was a dose escalation study in patients with any BRAF V600 mutation-positive solid tumor using a modified Rolling 6 Design (RSD). Part 2...
What is the current status of trial NCT01677741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2013-05-23. Estimated completion is 2020-12-04.
What conditions does trial NCT01677741 study?
This clinical trial studies the following conditions: Neoplasms, Brain.
What interventions are being tested in trial NCT01677741?
The interventions under investigation include: Dabrafenib (DRUG).
Who is sponsoring clinical trial NCT01677741?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01677741 being conducted?
This trial has 20 study locations across Arizona, California, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.